Search
News
Versigent Q2 2026 earnings: EBITDA margin expands on higher volumes
Versigent's (NYSE: VGNT) Q2 2026 net sales rose 10.8% to $2.44 billion, while diluted EPS increased to $1.64 from $1.51. Adjusted EBITDA climbed 24.8% to $272 million and margin expanded 120 basis points to 11.1%, supported by higher volumes and operating execution, although interest and tax expense held net margin to 4.8%. The company raised and tightened full-year sales guidance to $9.4-$9.6 billion but maintained its adjusted EBITDA and free cash flow ranges, as the sales revision reflected commodity pass-through and foreign exchange effects.
TradingKey
Wed, Aug 5
Pfizer Q2 2026 Earnings: Non-COVID Growth Raises Revenue Outlook
Pfizer’s Q2 2026 revenue rose 3% to $15.03 billion, with non-COVID revenue up 5% operationally, while adjusted diluted EPS was $0.77 versus $0.78 a year ago. A $4.3 billion non-cash intangible-asset impairment drove a reported loss of $0.04 per share despite nearly flat adjusted income. Growth in Eliquis, Padcev, Vyndaqel and Lorbrena offset steep declines in Paxlovid and Comirnaty. Pfizer raised the midpoint of 2026 revenue guidance to $61.5 billion and maintained adjusted EPS guidance of $2.80 to $3.00.
TradingKey
Wed, Aug 5
Brightstar Lottery Q2 2026 Earnings: EBITDA Rises Despite Revenue Decline
Brightstar Lottery’s Q2 2026 revenue fell 7% year over year to $584 million, as higher Italy Lotto service revenue amortization, the U.K. contract transition, and lower product sales offset 1.5% global same-store sales growth. Adjusted EBITDA increased 4% to $286 million and margin rose to 48.9%, while diluted EPS from continuing operations improved to $0.18 from a $0.47 loss. Quarterly operating cash flow was negative $1.34 billion after the $1.67 billion final Italy Lotto license payment. Brightstar reaffirmed its full-year 2026 outlook.
TradingKey
Wed, Aug 5
Havertys Q2 2026 Earnings: Sales Rise 7.7% as EPS Doubles
Havertys Q2 2026 revenue rose 7.7% to $194.9 million, comparable-store sales increased 8.0%, and diluted EPS doubled to $0.32. GAAP gross margin reached 61.4%, but excluding roughly $1.5 million of IEEPA tariff refunds, it was 60.7% versus 60.8% a year earlier. Six-month operating cash flow improved to $21.4 million, while the company maintained its 60.5%-61.0% full-year gross-margin outlook and raised variable SG&A expectations because of higher selling expenses. Store expansion also lifted planned 2026 capital expenditures to approximately $34 million.TradingKey
Wed, Aug 5
SOPHiA GENETICS Q2 2026 earnings: Revenue rises 27% as adjusted EBITDA loss narrows
SOPHiA GENETICS reported Q2 2026 revenue of $23.3 million, up 27% year over year, while basic and diluted loss per share narrowed to $0.30 from $0.33. IFRS net loss was roughly flat at $22.4 million, but adjusted EBITDA loss improved 27% to $8.8 million. Reported gross margin declined to 64.6% from 67.0%. U.S. and Liquid Biopsy growth supported revenue, the full-year revenue outlook rose to $94 million-$96 million, and cash reached $107.7 million following equity financing.
TradingKey
Wed, Aug 5
Marathon Petroleum Q2 2026 earnings: Refining margins drive profit growth
Marathon Petroleum's Q2 2026 revenue rose 53.8% to $51.99 billion, diluted EPS increased to $17.73 from $3.96, and adjusted EBITDA reached $8.46 billion. The main driver was Refining & Marketing margin expansion to $36.33 per barrel as crack spreads improved across all regions, more than offsetting lower throughput and higher unit operating costs. Midstream EBITDA advanced modestly, while Renewable Diesel swung to a $258 million adjusted EBITDA profit. MPC ended June with $7.77 billion in cash and returned over $2.8 billion to shareholders.
TradingKey
Wed, Aug 5
Revvity Q2 2026 earnings: Diagnostics and tariff refunds lift adjusted margins
Revvity’s second-quarter 2026 revenue rose about 1% to $730 million, while GAAP EPS from continuing operations increased to $0.48 from $0.47. Adjusted EPS advanced to $1.41 and adjusted operating margin reached 28.9%, aided by $16 million of tariff refunds and stronger Diagnostics profitability. Diagnostics delivered 11% pro forma organic growth, offsetting a 3% decline in Life Sciences. Quarterly operating cash flow increased to $191.9 million, and Revvity raised its pro forma full-year guidance while excluding its planned China Immunodiagnostics divestiture.
TradingKey
Wed, Aug 5
Pediatrix Q2 2026 earnings: Reimbursement gains offset volume declines
Pediatrix Medical Group’s Q2 2026 net revenue rose 4.0% to $487.8 million, and diluted GAAP EPS increased to $0.49 from $0.46. Adjusted EBITDA advanced to $76.4 million, while cash from continuing operations declined to $126.3 million. Recent acquisitions and a 4.0% improvement in same-unit reimbursement factors offset a 2.1% drop in same-unit patient volume. Higher clinical, administrative, and restructuring costs pushed operating income lower, though the company reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million.
TradingKey
Wed, Aug 5
ADM Q2 2026 earnings: Biofuel margins lift profit and guidance
ADM’s Q2 2026 results for the quarter ended June 30 featured net earnings of $908 million, diluted EPS of $1.87, and adjusted diluted EPS of $1.84, up 98% year over year. Total segment operating profit rose 75% to $1.45 billion, with gains across Ag Services & Oilseeds, Carbohydrate Solutions, and Nutrition. Better crushing and ethanol margins, supportive U.S. biofuel policy and Nutrition momentum drove the improvement. ADM raised full-year adjusted EPS guidance to $5.15-$5.60 from $4.15-$4.70.
TradingKey
Wed, Aug 5
Henry Schein Q2 2026 Earnings: Margin Gains Support Higher Guidance
Henry Schein’s Q2 2026 net sales increased 6.7% to $3.458 billion, including 4.6% internal growth, while GAAP diluted EPS rose to $0.82 from $0.70. Adjusted EBITDA reached $288 million, up 12.5%, and operating cash flow increased to $242 million. Organic momentum was strongest in Global Technology and dental merchandise, while wider margins and a lower diluted share count helped EPS grow faster than net income. Henry Schein raised FY2026 guidance to 4.5%-5.5% sales growth, $5.29-$5.39 in non-GAAP diluted EPS, and mid- to high-single-digit Adjusted EBITDA growth.
TradingKey
Wed, Aug 5
Qnity Q2 2026 earnings: Revenue rises 22% as GAAP profit falls
Qnity’s Q2 2026 net sales rose 22% year over year to $1.429 billion, while GAAP diluted EPS declined 34% to $0.59. Adjusted EPS increased 53% to $1.19 and adjusted operating EBITDA rose 24% to $431 million, as Interconnect Solutions grew 30% and Semiconductor Technologies grew 16%. Higher interest expense, transformation charges and other costs weighed on GAAP profit despite higher gross profit. Qnity also raised full-year 2026 guidance, including net sales of $5.55 billion to $5.65 billion and adjusted free cash flow of $600 million to $700 million.
TradingKey
Wed, Aug 5
Gartner Q2 2026 Earnings: EPS Rises 33.1% as Adjusted Revenue Grows 2.8%
Gartner’s Q2 2026 revenue declined 0.6% to $1.676 billion, but adjusted revenue excluding the divested Digital Markets operation rose 2.8%. GAAP diluted EPS increased 33.1% to $4.14, supported by 14.4% net income growth and a lower diluted share count. Free cash flow advanced 8.9% to $378 million. Operating income also increased about 15.7%, lifting the GAAP operating margin. Conferences grew 15.5%, Insights rose 2.1%, and Consulting fell 8.8%, while FX-neutral contract value increased 1.7% year over year.
TradingKey
Wed, Aug 5
Sequans Q2 2026 earnings: Product sales rise as gross margin contracts
Sequans Communications’ preliminary Q2 2026 results showed revenue of $7.5 million, down 8.4% year over year, while product sales rose 83.7%. Gross margin fell to 32.9% from 64.4% because the prior-year period benefited from Qualcomm license and services revenue and the current mix shifted toward products. The IFRS net loss widened to $9.8 million, although diluted loss per ADS narrowed to $0.65. Cash reached $21.0 million after Bitcoin sales helped fund the full redemption of convertible debt, while first-half operating cash outflow increased to $23.0 million.TradingKey
Wed, Aug 5
IDEAYA Q2 2026 earnings: Darovasertib NDA advances with $1.24 billion in cash
IDEAYA Biosciences’ Q2 2026 collaboration revenue rose sequentially to $8.9 million from $6.6 million, while net loss widened to $112.5 million as R&D and commercial-preparation costs increased. Cash, cash equivalents and marketable securities reached approximately $1.24 billion after June equity financing, supporting unchanged runway guidance into 2030. The main operating milestone was OptimUM-02’s positive progression-free survival result for the darovasertib combination, with an NDA submission underway through the FDA’s real-time oncology review program and several pipeline updates planned for the second half of 2026.
TradingKey
Wed, Aug 5
Leidos Q2 FY2026 Earnings: Revenue Rises as Margins Narrow
Leidos reported Q2 FY2026 revenue of $4.56 billion, up 7% year over year, while GAAP diluted EPS fell to $2.81 from $3.01. Adjusted EBITDA declined 2% to $631 million and its margin narrowed to 13.8%, but operating cash flow rose to $793 million and free cash flow reached $761 million. Homeland led segment growth, while lower medical disability exam volumes weighed on Health. Leidos also raised the low ends of its FY2026 revenue and non-GAAP EPS ranges and increased its operating cash flow outlook to approximately $1.85 billion.
TradingKey
Wed, Aug 5
Eve Q2 2026 earnings: Lower R&D narrows the net loss
Eve Holding’s Q2 2026 results showed a net loss of $34.2 million, down from $64.7 million a year earlier, as R&D expense fell to $28.9 million from $45.7 million. Quarterly cash consumption declined to $49.4 million, partly because some Embraer-related payments moved into Q3. Eve ended the quarter with $403.3 million in cash, cash equivalents and financial investments, while total liquidity reached $531.3 million. The pre-operational eVTOL developer expects full-year 2026 cash consumption of $250 million.TradingKey
Wed, Aug 5
Ball Q2 2026 Earnings: Shipments Rise as Operating Margin Narrows
Ball Corporation’s Q2 2026 revenue rose about 19.7% to $3.997 billion, comparable diluted EPS increased 14.4% to $1.03, and global aluminum packaging shipments grew 4.3%. Profit growth trailed sales as metal-linked pass-through pricing expanded revenue while North American operating and plant startup costs weighed on margins. South America delivered the largest regional earnings increase. Ball reiterated its 2026 goals, but negative first-half free cash flow means second-half cash conversion will be central to achieving the full-year target, while leverage has also increased from year-end.
TradingKey
Wed, Aug 5
DuPont Q2 2026 earnings: Adjusted EPS rises 48% on 4% sales growth
DuPont (NYSE: DD) reported second-quarter 2026 net sales of $1.819 billion, up 4% year over year, while adjusted EPS rose 48% to $1.88. Operating EBITDA increased 6% to $448 million and margin expanded 40 basis points to 24.6%, supported by organic growth and productivity. Continuing-operations cash flow also improved, with $400 million from operations and $326 million of transaction-adjusted free cash flow. The company raised full-year operating EBITDA and adjusted EPS guidance, citing strength in healthcare, industrial water and aerospace as support for its second-half outlook.
TradingKey
Wed, Aug 5
Waters Q2 2026 Earnings: Acquisition Doubles Revenue as GAAP Results Turn Negative
Waters' Q2 2026 revenue reached $1.645 billion, up 113% year over year after its Biosciences and Diagnostic Solutions acquisition, while organic revenue rose 7% reported and 9% in constant currency. The company posted a GAAP loss of $1.39 per share as acquisition-related amortization and fair-value step-ups weighed on reported earnings, but adjusted EPS increased 3% to $3.05. Operating cash flow improved to $200 million, and Waters raised full-year guidance to 7%-9% organic constant-currency growth and adjusted EPS of $14.45-$14.65 as end-market conditions broadened.
TradingKey
Wed, Aug 5
Wix Q2 2026 earnings: Revenue growth comes with weaker profitability
Wix.com’s Q2 2026 revenue rose 15% year over year to $563.1 million, while bookings increased 12% to $569.1 million. GAAP diluted EPS swung to a $1.78 loss from $0.98 in profit, and free cash flow fell to $52.6 million as operating expenses increased. Creative Subscriptions and Business Solutions revenue grew 15% and 14%, respectively. Wix maintained its full-year low- to mid-teens revenue growth outlook and expects Base44’s non-GAAP gross margin to reach about 60% in the second half as its proprietary AI model lowers compute costs.
TradingKey
Wed, Aug 5
Featured Tools
Top News
Amazon Stock Forecast: AMZN Needs a Close Above $258 as Q3 Tests Its AI Spending
Amazon Shares Plunge 11% After Hours as Q3 Revenue Misses Estimates, Free Cash Flow Negative $33.456 Billion
Marvell’s Proposed Acquisition of Lumentum Sparks Pre-Market Divergence in Optical Communications Stocks: MRVL Falls Over 11%, LITE Rises Over 4%, COHR Slips 0.63%
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
Amazon Q3 Earnings Preview: AWS Growth Expected to Rise to 41%, Wall Street Top Price Target $400